Management to host conference call and webcast at 4:30 pm ET on that dayBoca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio ...

BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...

A phase 2 study of INmune Bio’s TNF inhibitor in Alzheimer’s disease has missed its primary endpoint, wiping 60% off the biotech share price. As INmune CEO Raymond Tesi, M.D., said on an earnings call ...

Investing.com -- INmune Bio (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in ...

Shares in INmune Bio lost almost two-thirds of their value in premarket trading this morning as it emerged that its drug candidate for Alzheimer's disease flunked a highly anticipated phase 2 trial.

The company is targeting the release of top-line data for the XPro Phase 2 Alzheimer's trial in June, with specific emphasis on cognitive and functional endpoints. Plans to complete CORDStrom's BLA ...

INmune Bio Inc. (NASDAQ:INMB) stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro. The company ...

The FDA has blocked the small biotech INmune Bio from moving an Alzheimer’s disease therapy into a phase 2 clinical study on manufacturing concerns. INmune said after market Monday that it had ...

Shares of INmune Bio (NASDAQ:INMB) fell over 14% premarket on Friday after the immunology company launched a $13M securities offering. The firm entered into securities purchase agreements for the ...

MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a ...

INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday. The company will present findings from ...